## Note
nid: 1582321907012
model: AnKingOverhaul
tags: #AK_Original_Decks::Step_1::Zanki_Step_Decks::Zanki_Immunology_+_General_Pathology::Immunology, #AK_Step1_v11::#FirstAid::02_Immunology::04_Immunosuppressants::04_Therapeutic_Antibodies, #AK_Step1_v11::#FirstAid::02_Immunology::04_Immunosuppressants::04_Therapeutic_Antibodies::Ixekizumab, #AK_Step1_v11::#FirstAid::02_Immunology::04_Immunosuppressants::04_Therapeutic_Antibodies::Secukinumab, #AK_Step1_v11::#OME_banner::Basic_Science::07_Immunology, #AK_Step1_v11::#Pixorize::01_Immunology::04_B_&_T_Cells::14_Th17, #AK_Step1_v11::$AnKingAdds::FA2020::Immunology, #AK_Step1_v11::^Other::^HighYield::5-LowYield, #AK_Step1_v11::^Systems::Immunology::AKadds
markdown: false

### Text
<b>{{c1::Ixekizumab}}</b> and <b>{{c3::secukinumab}}</b> are
<u>monoclonal antibodies</u> against <b>{{c2::IL-17A}}</b> used to
treat <i>psoriasis</i> and <i>psoriatic arthritis</i>

### Extra
<img src="paste-d0d16e877abc94d688391779fe9800e75aa7f85c.jpg">

### Lecture Notes


### Missed Questions


### Pathoma


### Boards and Beyond


### First Aid


### Sketchy


### Pixorize


### Physeo


### OME
<div class="ome-widget">
  <a href=
  "https://onlinemeded.org/spa/immunology?ref=anki"><img src=
  "_OME_AnkiFlashcards_Topic_4.png"></a>
</div>

### Additional Resources
IL-23 stimulates Th17 cells which leads to Crohns, UC, and
psoriasis/psoriatic arthritis. IL-23 also leads to stimulation of
<u>gamma-delta T</u> cells which is important for the development
of psoriatic arthritis.
<div>
  Newly approved treatment for UC. <i>IL-23 is considered the
  <b>central cytokine</b></i> in Crohn's and possibly UC (blocked
  by <u>tildrakizumab</u>)
</div>

### One by one

